Humanized immune system (HIS) mice have been increasingly utilized for their enhanced clinical translation in immuno-oncology research. These mice have been widely used in combination with human tumor (patient- or cell-derived) xenografts for the evaluation of biologics, cancer vaccines, and cell-based therapies.
HIS mice can vary both in the overall reconstitution of human immune cells and distribution across cell types from donor to donor, and tumor type may influence the extent of human immune cell infiltration into tumors. To maximize the success of studies conducted with these powerful models, they must be carefully designed with a focus on donor variability, impact of humanization on tumor growth kinetics, and proper power analysis.
This webinar will review key considerations for human tumor xenograft studies using HIS mice, illustrating these concepts using data from a study with huNOG-EXL mice implanted with human lung cancer CDX and PDX. This study provides a comprehensive look at a HIS mouse that reconstitutes multiple human lineages, both lymphoid and myeloid, in the context of a human lung cancer model.
Date: Tuesday, February 2, 2021
Time: 17:00 CET
Venue: Online
Dr. Janell Richardson will review the degree of variance between different stem cell donors, tumor types, and immune cell reconstitution (tissue, phenotype and/or kinetics) within a huNOG-EXL lung cancer model.
This presentation will also cover:
- An overview of the key factors, including donor variability and proper power analysis
- Recommendations for selection of the most appropriate HIS model
- Best practices for HIS model xenograft studies derived from the experience of Taconic Biosciences scientists in both internal studies and collaborations across industry
Speaker
 |
Janell Richardson, PhDDr.
Janell Richardson has 15 years of in vivo pharmacology experience. She received her doctorate in 2012 from Georgetown University- Pharmacology. She continued on to a post-doctoral fellowship and subsequently moved into industry in 2015. In the commercial sector, she led an early target identification in vivo pharmacology team. In 2018, she joined Taconic as a field scientist and currently, assumed a new role in co-leading Taconic’s R&D efforts |
Organized by:
